Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001565742 | SCV001789144 | likely pathogenic | not provided | 2020-11-24 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 23744890, 32672072) |
Labcorp Genetics |
RCV001882667 | SCV002276494 | uncertain significance | Amyotrophic lateral sclerosis type 1 | 2021-09-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SOD1 protein function. This variant is also known as Phe64Leu. This variant has been observed in individual(s) with amyotrophic lateral sclerosis (PMID: 23744890). This variant is not present in population databases (ExAC no frequency). This sequence change replaces phenylalanine with leucine at codon 65 of the SOD1 protein (p.Phe65Leu). The phenylalanine residue is highly conserved and there is a small physicochemical difference between phenylalanine and leucine. |
Athena Diagnostics | RCV001565742 | SCV002771832 | uncertain significance | not provided | 2022-09-12 | criteria provided, single submitter | clinical testing |